ReviewFuture oncology (London, England)2026

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel.

Andrea Ardizzoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.